Work

Lack of intestinal Mucin-1 impairs intestinal epithelial barrier and promotes metabolic dysfunction-associated steatotic liver disease in male mice

Year: 2025

Type: article

Abstract: Accumulating evidence suggests that a compromised intestinal epithelial barrier (IEB) contributes to the progression of metabolic dysfunction-associated steatotic liver disease (MASLD); however, the exact mechanisms remain unclear. Here we reveal that intestinal mucin 1 (MUC1) levels and glycosylation are decreased in both humans and male mice with MASLD. Enterocyte-specific Muc1 knockout aggravates high-fat diet (HFD)-induced IEB impairment and MASLD progression in male mice. Mechanistically, HFD feeding reduces the glycosylation of intestinal epithelial MUC1, triggering its clathrin-mediated endocytosis and NEDD4-mediated lysosomal degradation, which subsequently induces β-Catenin degradation and ultimately impaires the IEB. Notably, enterocyte-specific overexpression of cytoplasmic-tail-deleted MUC1 protects against IEB impairment and mitigates MASLD progression. These findings indicate that reduced intestinal epithelial MUC1 levels facilitate the progression of MASLD. Preserving the glycosylation and levels of intestinal MUC1 to maintain IEB integrity is a potential therapeutic strategy to explore for MASLD. Intestinal mucin 1 (MUC1) is a glycosylated protein that maintains intestinal epithelial barrier (IEB) integrity. Here, the authors show that reduced intestinal MUC1 levels and glycosylation facilitate metabolic dysfunction-associated steatotic liver disease (MASLD) progression by impairing IEB integrity, via clathrin-mediated endocytosis and NEDD4-mediated lysosomal degradation of MUC1 (triggered by decreased glycosylation).

Source: Nature Communications

DOI: 10.1038/s41467-025-67034-7